Comparative Pharmacology
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus INDERIDE 40 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus INDERIDE 40 25.
ACEBUTOLOL HYDROCHLORIDE vs INDERIDE-40/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker) with intrinsic sympathomimetic activity (ISA). Competitively blocks catecholamine binding at cardiac beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure. ISA provides mild beta-receptor stimulation, decreasing the extent of resting bradycardia and lipid changes.
Inderide-40/25 is a combination of propranolol (non-cardioselective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol reduces heart rate, myocardial contractility, and renin secretion via beta-adrenergic receptor blockade. Hydrochlorothiazide inhibits Na+/Cl- cotransporter in distal convoluted tubule, increasing excretion of Na+, Cl-, and water; also reduces peripheral vascular resistance.
Dose: 200-800 mg/day orally in 1-2 divided doses. Initially 200 mg twice daily; may increase to 400 mg twice daily as needed.
One tablet (40 mg propranolol HCl/25 mg hydrochlorothiazide) orally twice daily; may increase to maximum of 160 mg propranolol/100 mg hydrochlorothiazide per day in divided doses.
None Documented
None Documented
3-4 hours for acebutolol; 8-13 hours for diacetolol (active metabolite); clinically significant in renal impairment
Propranolol: 3-6 hours (terminal); clinical context: dosing 2-3 times daily due to short half-life; may accumulate in hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal); clinical context: longer in renal impairment.
Renal: 30-40% as unchanged drug and 50-60% as diacetolol; fecal: ~10%
Propranolol: extensively metabolized in liver via CYP2D6 and glucuronidation; <1% excreted unchanged in urine. Hydrochlorothiazide: ~70% excreted unchanged in urine via tubular secretion.
Category C
Category C
Beta Blocker
Beta Blocker and Thiazide Diuretic